MELPIDA

Phase 1Biologic

EElpida Therapeutics SPC

MELPIDA is one of 4 biologic programs targeting Spastic paraplegia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spastic ParaplegiaActive, not recruiting

Spasticity, MuscleRecruiting

Spastic ParaplegiaPhase 1

Active, not recruiting

Spasticity, MusclePreclinical

Recruiting

Competition

Competitive Landscape

5 competitors in Spastic Paraplegia

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Opfolda

1 3

Calcium Folinate

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

1 4

MELPIDA

EElpida Therapeutics SPC

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Active, not recruiting

Spastic Paraplegia

NCT06069687

Q4 2030

PreclinicalRecruiting

Spasticity, Muscle

NCT05518188

Clinical

Trials by Indication[1]

Spastic paraplegia1 trial

Administration of MELPIDA to Determine the Safety and Efficacy for Patients With Spastic Paraplegia Type 50

Active, not recruiting·TThe Hospital for Sick Children·Phase 1·NCT06069687·1 enrolled

Spasticity, Muscle1 trial

A Phase 1/2 Open-label Intrathecal Administration of MELPIDA to Determine Its Safety and Efficacy for Patients With Spastic Paraplegia Type 50 (SPG50) Caused by Mutation in the AP4M1 Gene.

Recruiting·EElpida Therapeutics SPC·Preclinical·NCT05518188·4 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for MELPIDA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MELPIDA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MELPIDA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Elpida Therapeutics SPC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: EElpida Therapeutics SPC

MELPIDA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2030

Trials by Indication[1]

Spastic paraplegia1 trial

Spasticity, Muscle1 trial

References

Drug Info

Quick Facts

Related News